Hip Pelvis.  2015 Sep;27(3):173-178. 10.5371/hp.2015.27.3.173.

Is Taking an Antiplatelet Agent a Contraindication for Early Surgery in Displaced Femur Neck Fracture?

• Yoo HS
• Cho YH
• Byun YS
• Kim MG

• KMID: 2069147
• DOI: http://doi.org/10.5371/hp.2015.27.3.173

Abstract

PURPOSE
The purpose of this study was to evaluate whether we have to stop the antiplatelet agents prior to hemiarthroplasty surgery in patients with displaced femur neck fractures to reduce postoperative complications.
MATERIALS AND METHODS
We enrolled forty-three patients with displaced femur neck fractures who were treated by bipolar hemiarthroplasty and were taking antiplatelet agents. Group I included 21 patients who discontinued antiplatelet agents and had delayed operations at an average 5.7 days and group II included 22 patients who had had early operations within 24 hours without stopping the antiplatelet agents. We compared the pre- and postoperative levels of hemoglobin, the volume of postoperative transfusion requirement and complications. Student's t-test and chi-square test were used for statistical analysis.
RESULTS
The average differences between preoperative and postoperative hemoglobin was 1.4+/-0.4 g/dL decrease in group I and 2.1+/-0.5 g/dL decrease in group II (P<0.001). Patients who received a blood transfusion were 11 in group I and 13 in group II (P=0.66). Total number of blood transfusion was 13 pints in group I and 18 pints in group II (P=0.23). Pneumonia occurred in one patient in each group. Four pressure sores and three diaper rashes were developed in group I. But there were no patients requiring massive transfusion, reoperation due to hematoma and infection in each group.
CONCLUSION
Although continuous taking of antiplatelet agents in displaced femur neck fracture is associated with an increased risk of postoperative bleeding, taking an antiplatelet agent itself is not a contraindication of early surgery.

Keyword

Displaced femur; Neck fracture; Antiplatelet agent; Early surgery; Hemiarthroplasty

MeSH Terms

Blood Transfusion
Diaper Rash
Femoral Neck Fractures*
Femur Neck*
Femur*
Hematoma
Hemiarthroplasty
Hemorrhage
Humans
Platelet Aggregation Inhibitors
Pneumonia
Postoperative Complications
Pressure Ulcer
Reoperation
Platelet Aggregation Inhibitors

Reference

1. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997; 7:407–413.

2. Parker M, Johansen A. Hip fracture. BMJ. 2006; 333:27–30.

3. Roche JJ, Wenn RT, Sahota O, Moran CG. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ. 2005; 331:1374.

4. Inman DS, Michla Y, Partington PF. Perioperative management of trauma patients admitted on clopidogrel (Plavix). A survey of orthopaedic departments across the United Kingdom. Injury. 2007; 38:625–630.

5. Lavelle WF, Demers Lavelle EA, Uhl R. Operative delay for orthopedic patients on clopidogrel (plavix): a complete lack of consensus. J Trauma. 2008; 64:996–1000.

6. Al-Ani AN, Samuelsson B, Tidermark J, et al. Early operation on patients with a hip fracture improved the ability to return to independent living. A prospective study of 850 patients. J Bone Joint Surg Am. 2008; 90:1436–1442.

7. Orosz GM, Magaziner J, Hannan EL, et al. Association of timing of surgery for hip fracture and patient outcomes. JAMA. 2004; 291:1738–1743.

8. Maheshwari R, Acharya M, Monda M, Pandey R. Factors influencing mortality in patients on antiplatelet agents presenting with proximal femoral fractures. J Orthop Surg (Hong Kong). 2011; 19:314–316.

9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348:1329–1339.

10. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494–502.

11. Llau JV, De Andrés J, Gomar C, Gómez-Luque A, Hidalgo F, Torres LM. Anticlotting drugs and regional anaesthetic and analgesic techniques: comparative update of the safety recommendations. Eur J Anaesthesiol. 2007; 24:387–398.

12. Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med. 2003; 28:172–197.

13. American Society of Anesthesiologists. New classification of physical status. Anesthesiology. 1963; 24:111.

14. Johnell O, Kanis JA. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int. 2004; 15:897–902.

15. Morris AH, Zuckerman JD. AAOS Council of Health Policy and Practice, USA. American Academy of Orthopaedic Surgeons. National Consensus Conference on improving the continuum of care for patients with hip fracture. J Bone Joint Surg Am. 2002; 84:670–674.

16. McLaughlin MA, Orosz GM, Magaziner J, et al. Preoperative status and risk of complications in patients with hip fracture. J Gen Intern Med. 2006; 21:219–225.

17. Shiga T, Wajima Z, Ohe Y. Is operative delay associated with increased mortality of hip fracture patients? Systematic review, meta-analysis, and meta-regression. Can J Anaesth. 2008; 55:146–154.

18. Parker MJ, Anand JK. What is the true mortality of hip fractures? Public Health. 1991; 105:443–446.

19. Hamlet WP, Lieberman JR, Freedman EL, Dorey FJ, Fletcher A, Johnson EE. Influence of health status and the timing of surgery on mortality in hip fracture patients? Am J Orthop (Belle Mead NJ). 1997; 26:621–627.

20. Villar RN, Allen SM, Barnes SJ. Hip fractures in healthy patients: operative delay versus prognosis. Br Med J (Clin Res Ed). 1986; 293:1203–1204.

21. Bredahl C, Nyholm B, Hindsholm KB, Mortensen JS, Olesen AS. Mortality after hip fracture: results of operation within 12 h of admission. Injury. 1992; 23:83–86.

22. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007; 297:159–168.

23. Weber AA, Braun M, Hohlfeld T, Schwippert B, Tschöpe D, Schrör K. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol. 2001; 52:333–336.

24. Llau JV, Lopez-Forte C, Sapena L, Ferrandis R. Perioperative management of antiplatelet agents in noncardiac surgery. Eur J Anaesthesiol. 2009; 26:181–187.

25. Haidar R, Taher AT. How long should we delay hip fracture surgery for elderly patients on clopidogrel? Injury. 2011; 42:1509–1510.

26. Johansen A, White J, Turk A. Clopidogrel therapy: implications for hip fracture surgery. Injury. 2008; 39:1188–1190.

27. Harty JA, McKenna P, Moloney D, D'Souza L, Masterson E. Anti-platelet agents and surgical delay in elderly patients with hip fractures. J Orthop Surg (Hong Kong). 2007; 15:270–272.

28. Chechik O, Amar E, Khashan M, Kadar A, Rosenblatt Y, Maman E. In support of early surgery for hip fractures sustained by elderly patients taking clopidogrel: a retrospective study. Drugs Aging. 2012; 29:63–68.

29. Collinge CA, Kelly KC, Little B, Weaver T, Schuster RD. The effects of clopidogrel (Plavix) and other oral anticoagulants on early hip fracture surgery. J Orthop Trauma. 2012; 26:568–573.